Recommendations for the Management of the Haematological and Onco-haematological Aspects of Gaucher Disease

Overview

Journal Br J Haematol

Specialty Hematology

Date 2007 Jul 28

PMID 17655728

Citations 29

Authors

Derralynn Hughes

Maria Domenica Cappellini

Marc Berger

Jan van Droogenbroeck

Maaike de Fost

Dragana Janic

Theodore Marinakis

Hanna Rosenbaum

Jesus Villarubia

Elena Zhukovskaya

Carla Hollak

Affiliations

Soon will be listed here.

Abstract

Current knowledge of the haematological and onco-haematological complications of type 1 Gaucher disease has been reviewed with the aim of identifying best clinical practice for treatment and disease management. It was concluded that: (i) Awareness of typical patterns of cytopenia can help clinicians distinguish haematological co-morbidities. (ii) Red blood cell studies and complete iron metabolism evaluation at baseline are recommended. (iii) Haemoglobin levels defining anaemia should be raised and used in Gaucher disease treatment and monitoring. (iv) Surgeons should be aware of potential bleeding complications during surgery in Gaucher patients. The higher incidence of multiple myeloma in Gaucher disease suggests that Gaucher patients should have their immunoglobulin profile determined at diagnosis and monitored every 2 years (patients <50 years) or every year (patients >50 years). If monoclonal gammopathy of undetermined significance (MGUS) is found, general MGUS guidelines should be followed. Future studies should focus on the utility of early treatment to prevent immunoglobulin abnormalities and multiple myeloma.

Citing Articles

The Complexities of Diagnosis with Co-Existing Gaucher Disease and Hemato-Oncology-A Case Report and Review of the Literature.

Sudul P, Piatkowska-Jakubas B, Pawlinski L, Galazka K, Sacha T, Kiec-Wilk B J Clin Med. 2023; 12(17).

PMID: 37685585 PMC: 10488105. DOI: 10.3390/jcm12175518.

Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications.

Linari S, Castaman G J Clin Med. 2022; 11(23).

PMID: 36498496 PMC: 9735904. DOI: 10.3390/jcm11236920.

Genetic Analysis of Acid β-Glucosidase in Patients with Multiple Myeloma from Central Taiwan: A Small-Cohort Case-Control Study.

Lin W, Tsai F Biomed Hub. 2022; 6(3):138-144.

PMID: 35083226 PMC: 8740171. DOI: 10.1159/000519704.

Novel Management and Screening Approaches for Haematological Complications of Gaucher's Disease.

Giraldo P, Andrade-Campos M J Blood Med. 2021; 12:1045-1056.

PMID: 34908889 PMC: 8665828. DOI: 10.2147/JBM.S279756.

Non-immune Hemolysis in Gaucher Disease and Review of the Literature.

Hershkop E, Bergman I, Kurolap A, Dally N, Feldman H Rambam Maimonides Med J. 2021; 12(3).

PMID: 34270405 PMC: 8284991. DOI: 10.5041/RMMJ.10446.

References

Katz K, Tamary H, Lahav J, Soudry M, Cohen I . Increased operative bleeding during orthopaedic surgery in patients with type I Gaucher disease and bone involvement. Bull Hosp Jt Dis. 2000; 58(4):188-90. View

Gielchinsky Y, Elstein D, Hadas-Halpern I, Lahad A, Abrahamov A, Zimran A . Is there a correlation between degree of splenomegaly, symptoms and hypersplenism? A study of 218 patients with Gaucher disease. Br J Haematol. 1999; 106(3):812-6. DOI: 10.1046/j.1365-2141.1999.01616.x. View

Corbett G, Darbyshire P, Besley G, Parker A . Adult Gaucher disease in association with acute leukaemia. Postgrad Med J. 1987; 63(744):899-900. PMC: 2428644. DOI: 10.1136/pgmj.63.744.899. View

Pratt P, Kochwa S, ESTREN S . Immunoglobulin abnormalities in Gaucher's disease. Report of 16 cases. Blood. 1968; 31(5):633-40. View

Salky B, KREEL I, Gelernt I, Bauer J, AUFSES Jr A . Splenectomy for Gaucher's disease. Ann Surg. 1979; 190(5):592-4. PMC: 1344537. DOI: 10.1097/00000658-197911000-00006. View

Hollak C, Evers L, Aerts J, van Oers M . Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis. 1997; 23(2):201-12. DOI: 10.1006/bcmd.1997.0137. View

Weinreb N, Charrow J, Andersson H, Kaplan P, Kolodny E, Mistry P . Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002; 113(2):112-9. DOI: 10.1016/s0002-9343(02)01150-6. View

Poll L, Koch J, Willers R, Aerts H, Scherer A, Haussinger D . Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis. 2002; 28(2):209-20. DOI: 10.1006/bcmd.2002.0511. View

Mistry P, Germain D . Phenotype variations in Gaucher disease. Rev Med Interne. 2006; 27 Suppl 1:S3-10. DOI: 10.1016/s0248-8663(06)80002-0. View

10.

Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D . Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis. 2005; 34(3):197-200. DOI: 10.1016/j.bcmd.2005.03.004. View

11.

Krause J, Bures C, Lee R . Acute leukaemia and Gaucher's disease. Scand J Haematol. 1979; 23(2):115-8. DOI: 10.1111/j.1600-0609.1979.tb02681.x. View

12.

Kyle R, Therneau T, Rajkumar S, Larson D, Plevak M, Offord J . Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354(13):1362-9. DOI: 10.1056/NEJMoa054494. View

13.

Nagral A, Mehta A, Gomes A, Ellis G, Jackson B, Sabin C . Serum soluble transferrin receptor in the diagnosis of iron deficiency in chronic liver disease. Clin Lab Haematol. 1999; 21(2):93-7. DOI: 10.1046/j.1365-2257.1999.00202.x. View

14.

Marodi L, Kaposzta R, Toth J, Laszlo A . Impaired microbicidal capacity of mononuclear phagocytes from patients with type I Gaucher disease: partial correction by enzyme replacement therapy. Blood. 1995; 86(12):4645-9. View

15.

Micheva I, Marinakis T, Repa C, Kouraklis-Symeonidis A, Vlacha V, Anagnostopoulos N . Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal. Blood Cells Mol Dis. 2006; 36(2):298-307. DOI: 10.1016/j.bcmd.2005.12.029. View

16.

Charrow J, Andersson H, Kaplan P, Kolodny E, Mistry P, Pastores G . The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000; 160(18):2835-43. DOI: 10.1001/archinte.160.18.2835. View

17.

Marti G, Ryan E, Papadopoulos N, Barton N, Fleischer T, Rick M . Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol. 1988; 29(4):189-94. DOI: 10.1002/ajh.2830290403. View

18.

Lin A, Ryu J, Harvey D, Sieracki B, Scudder S, Wun T . Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin. Gynecol Oncol. 2006; 102(1):98-102. DOI: 10.1016/j.ygyno.2005.11.031. View

19.

Nairz M, Weiss G . Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis. Wien Klin Wochenschr. 2006; 118(15-16):442-62. DOI: 10.1007/s00508-006-0653-7. View

20.

Lester T, Grabowski G, Goldblatt J, Leiderman I, Zaroulis C . Immune thrombocytopenia and Gaucher's disease. Am J Med. 1984; 77(3):569-71. DOI: 10.1016/0002-9343(84)90124-4. View